Furthermore, BCX9930 is another oral CFD inhibitor used in phase II clinical trials for the treatment of PNH (NCT04702568) and C3 glomerulopathy (NCT05162066). Here, CFD is linked to paroxysmal nocturnal hemoglobinuria.